3619 POSTER Factors Affecting Time From Surgery to Adjuvant Chemotherapy for Early Breast Cancer in a Rural and Urban Medical Oncology Unit – a Retrospective Cohort Study

2011 ◽  
Vol 47 ◽  
pp. S264-S265
Author(s):  
P.N. Fox ◽  
M.D. Chatfield ◽  
J. Beith ◽  
K. Turley ◽  
P.S. Grimison
2019 ◽  
Vol 15 (23) ◽  
pp. 2733-2741
Author(s):  
Antonis Valachis ◽  
Marie Sundqvist ◽  
Lena Carlsson ◽  
Bing Li ◽  
Flaminia Chiesa ◽  
...  

Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting. Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden. Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation. Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer.


2015 ◽  
Vol 54 (5) ◽  
pp. 704-711 ◽  
Author(s):  
Lærke Toftegård Andersen ◽  
Nis Palm Suppli ◽  
Susanne Oksbjerg Dalton ◽  
Niels Kroman ◽  
Jacob Rosenberg ◽  
...  

PLoS Medicine ◽  
2019 ◽  
Vol 16 (12) ◽  
pp. e1003006 ◽  
Author(s):  
Ewan Gray ◽  
Joachim Marti ◽  
Jeremy C. Wyatt ◽  
David H. Brewster ◽  
Peter S. Hall ◽  
...  

2009 ◽  
Vol 100 (8) ◽  
pp. 1479-1484 ◽  
Author(s):  
Masaaki Kawai ◽  
Shinichi Kuriyama ◽  
Akihiko Suzuki ◽  
Yoshikazu Nishino ◽  
Takanori Ishida ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document